Annexin Pharmaceuticals AB (publ) (STO: ANNX)
Sweden flag Sweden · Delayed Price · Currency is SEK
0.498
-0.008 (-1.58%)
Nov 29, 2024, 5:29 PM CET

ANNX Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
9.378.0112.2910.710.987.53
Upgrade
Research & Development
43.3136.0328.3742.1333.6421.38
Upgrade
Operating Expenses
52.6844.0440.6652.8344.6228.91
Upgrade
Operating Income
-52.68-44.04-40.66-52.83-44.62-28.91
Upgrade
Interest Expense
---0-1.86-0.5-0.03
Upgrade
Interest & Investment Income
0.180.12----
Upgrade
Earnings From Equity Investments
---0.95--
Upgrade
Currency Exchange Gain (Loss)
0.06-0.14-0.071.590.890.58
Upgrade
Pretax Income
-52.45-44.05-40.73-52.14-44.24-28.36
Upgrade
Net Income
-52.45-44.05-40.73-52.14-44.24-28.36
Upgrade
Net Income to Common
-52.45-44.05-40.73-52.14-44.24-28.36
Upgrade
Shares Outstanding (Basic)
365167146826218
Upgrade
Shares Outstanding (Diluted)
365167146826218
Upgrade
Shares Change (YoY)
130.52%14.23%78.30%33.40%247.79%42.77%
Upgrade
EPS (Basic)
-0.14-0.26-0.28-0.64-0.72-1.60
Upgrade
EPS (Diluted)
-0.14-0.26-0.28-0.64-0.72-1.60
Upgrade
Free Cash Flow
-52.56-43.4-41.17-45.02-39.2-25.73
Upgrade
Free Cash Flow Per Share
-0.14-0.26-0.28-0.55-0.64-1.45
Upgrade
EBITDA
-52.49-43.85-40.46-52.63-44.43-28.71
Upgrade
D&A For EBITDA
0.190.190.190.190.190.19
Upgrade
EBIT
-52.68-44.04-40.66-52.83-44.62-28.91
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.